Cytogenetic and myelodysplastic alterations after autologous hemopoietic stem cell transplantation

Giorgio Lambertenghi Deliliers, Claudio Annaloro, Ermanno Pozzoli, Alessandro Oriani, Aldo Della Volpe, Davide Soligo, Daniela Lambertenghi Deliliers, Elena Tagliaferri, Vanda Bertolli, Lorenza Romitti

Research output: Contribution to journalArticlepeer-review


Secondary myelodysplastic syndrome/acute myelogenous leukemia (MDS/AML) are today considered a primary complication of autologous hematopoietic stem cell transplantation. In our Center, 83 autografted patients underwent bone marrow (BM) biopsy and cytogenetic analysis at fixed intervals. Twelve patients developed non-clonal cytogenetic abnormalities and 10 patients clonal abnormalities, five of whom (three -7, one -5 and one t(9;11)) developed secondary MDS/AML. MDS was also diagnosed in two patients with a normal karyotype. In brief, seven patients (three males, four females; median age 36 years) developed MDS/AML 12-48 months (median 14) after autografting. The FAB diagnosis was AML-M2 in one, chronic myelomonocytic leukemia in two and refractory anemia with excess of blasts in transformation in four cases. Two patients presented a BM biopsy picture of MDS with fibrosis; none of them experienced leukemic transformation. Four MDS patients died, three of leukemic transformation and one of BM insufficiency; the two remaining patients are still living and untransformed. Our data underline the leukemogenic role of previous treatments, even if it is not possible to exclude that underlying disease and/or conditioning therapy may be involved.

Original languageEnglish
Pages (from-to)291-297
Number of pages7
JournalLeukemia Research
Issue number3
Publication statusPublished - Mar 1999


  • Autologous transplantation
  • Bone marrow biopsy
  • Cytogenetics
  • Secondary myelodysplasia

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Cytogenetic and myelodysplastic alterations after autologous hemopoietic stem cell transplantation'. Together they form a unique fingerprint.

Cite this